Secondary VTE prevention study: time to first recurrence of VTE, major or minor bleeding events, and PTS, on-treatment, for confirmed inherited patients with thrombophilia
| . | Confirmed inherited thrombophilia (only FVL and/or PT gene) (N = 44) . |
|---|---|
| Recurrence of VTE, n (%) | |
| At 3 mo | 1 (2.3) |
| At 6 mo | 1 (2.3) |
| At 12 mo | 1 (2.3) |
| Any bleeding event, n (%) | |
| At 3 mo | 12 (27.3) |
| At 6 mo | 14 (31.8) |
| At 12 mo | 16 (36.4) |
| MBE, n (%) | |
| At 3 mo | 0 |
| At 6 mo | 0 |
| At 12 mo | 0 |
| CRNM, n (%) | |
| At 3 mo | 0 |
| At 6 mo | 0 |
| At 12 mo | 0 |
| PTS, n (%) | |
| At 3 mo | 2 (4.5) |
| At 6 mo | 3 (6.8) |
| At 12 mo | 3 (6.8) |
| . | Confirmed inherited thrombophilia (only FVL and/or PT gene) (N = 44) . |
|---|---|
| Recurrence of VTE, n (%) | |
| At 3 mo | 1 (2.3) |
| At 6 mo | 1 (2.3) |
| At 12 mo | 1 (2.3) |
| Any bleeding event, n (%) | |
| At 3 mo | 12 (27.3) |
| At 6 mo | 14 (31.8) |
| At 12 mo | 16 (36.4) |
| MBE, n (%) | |
| At 3 mo | 0 |
| At 6 mo | 0 |
| At 12 mo | 0 |
| CRNM, n (%) | |
| At 3 mo | 0 |
| At 6 mo | 0 |
| At 12 mo | 0 |
| PTS, n (%) | |
| At 3 mo | 2 (4.5) |
| At 6 mo | 3 (6.8) |
| At 12 mo | 3 (6.8) |